Resmed Bulls Think Acquisition Timing Looks Awkward

Dow Jones07-21

0021 GMT - ResMed's bulls at Canaccord Genuity think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 20, 2026 20:21 ET (00:21 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653999244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 08:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653999244","market":"fut","top_or_hot":-1,"title":"Resmed Bulls Think Acquisition Timing Looks Awkward","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0021 GMT - ResMed's bulls at <a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 20, 2026 20:21 ET (00:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Resmed Bulls Think Acquisition Timing Looks Awkward</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResmed Bulls Think Acquisition Timing Looks Awkward\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-21 08:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0021 GMT - ResMed's bulls at <a href=\"https://laohu8.com/S/CCORF\">Canaccord Genuity</a> think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 20, 2026 20:21 ET (00:21 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B5TLWC47.USD","symbol_name":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653999244","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653999244","pubTimestamp":1784593260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0021 GMT - ResMed's bulls at Canaccord Genuity think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05.  Dow Jones NewswiresJuly 20, 2026 20:21 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4504":"桥水持仓","BK7501":"新冠治疗股","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4588":"碎股","BK7007":"医疗保健设备","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD":"瑞思迈","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","RMD.AU":"Resmed DRC"},"translate_title":"瑞思迈看涨者认为收购时机看起来很尴尬","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":0.9,"LGHT":0.6,"RMD":0.9},"content_text":"0021 GMT - ResMed's bulls at Canaccord Genuity think its latest acquisition has come at an awkward time for the breath-tech supplier. The broker's analysts say investors were just starting to get excited about ResMed's gross-margin expansion and potential to push earnings leverage, which may be challenged by the acquisition of the Noctrix startup. The analysts do see opportunity in trying to address restless leg syndrome, which is Noctrix's focus, but warn that ResMed shares are struggling for direction ahead of the company's 4Q update. Canaccord Genuity cuts its target price on ResMed's ASX-listed stock by 10% to 40.00 Australian dollars. Shares are down 0.5% at A$28.05. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 20, 2026 20:21 ET (00:21 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653999244","isCrawlerRequest":true}